Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency

New England Journal of Medicine

Volumn 339, Issue 9, 1998, Pages 599-603

  Bilezikian, John P ^a   Morishima, Akira ^a   Bell, Jennifer ^a   Grumbach, Melvin M ^b  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; CONJUGATED ESTROGEN; ESTROGEN;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; CASE REPORT; DENSITOMETRY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME DEFICIENCY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; GENE MUTATION; GENETIC DISORDER; HUMAN; MALE; OSTEOPOROSIS; POINT MUTATION; PRIORITY JOURNAL;

ADULT; AROMATASE; BONE DENSITY; BONE REMODELING; ESTROGENS, CONJUGATED (USP); GONADAL STEROID HORMONES; HUMANS; MALE; OSTEOPOROSIS;

EID: 0032572929     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199808273390905     Document Type: Article

References (42)

1. Bonjour J-P, Rizzoli R. Bone acquisition in adolescence. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego, Calif.: Academic Press, 1996:465-76.
2. Bachrach LK, Guido D, Katzman D, Litt IF, Marcus R. Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics 1990;86:440-7
3. Warren MP, Brooks-Gunn J, Hamilton LH, Warren LF, Hamilton WG. Scoliosis and fractures in young ballet dancers: relation to delayed menarche and secondary amenorrhea. N Engl J Med 1986;314:1348-53. [Erratum, N Engl J Med 1986;315:905.]
4. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WF Jr. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987;106:354-61.
5. Finkelstein JS, Neer RM, Biller BMK, Crawford JD, Klibanski A. Osteopenia in men with a history of delayed puberty. N Engl J Med 1992; 326:600-4.
6. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995;16:87-116.
7. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331: 1056-61. [Erratum, N Engl J Med 1995;332:131.]
8. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80: 3689-98.
9. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997;337:91-5.
10. Katzman DK, Bachrach LK, Carter DR, Marcus R. Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab 1991;73:1332-9.
11. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992;7:137-45.
12. Genant HK, Engelke K, Fuerst R, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996;11:707-30.
13. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB. Effects of low doses of transdermal 17beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992;74: 1396-400.
14. Godsland IF, Gangar KF, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846-53.
15. Sharp SC, Diamond MP. Sex steroids and diabetes. Diabetes Rev 1995;1:318-42.
16. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995;273:199-208. [Erratum, JAMA 1995;274:1676.]
17. Bagatell CJ, Knopp RH, Rivier JE, Bremner WJ. Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men. J Clin Endocrinol Metab 1994;78:855-61.
18. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier RE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 1994;79:561-7.
19. Asscheman H, Gooren LJ, Megens JA, Nauta J, Kloosterboer HJ, Eikelboom F. Serum testosterone level is the major determinant of the male-female differences in serum levels of high-density lipoprotein (HDL) cholesterol and HDL2 cholesterol. Metabolism 1994;43:935-9.
20. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 1993;90:11162-6.
21. Korach KS. Insights from the study of animals lacking functional estrogen receptor. Science 1994;266:1524-7.
22. Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P, Harada H. Aromatase deficiency in a female who is a compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J Clin Endocrinol Metab 1997;82:1739-45.
23. Shozu M, Akasofu K, Harada T, Kubota Y. A new cause of female pseudohermaphroditism: placental aromatase deficiency. J Clin Endocrinol Metab 1991;72:560-6.
24. Ito Y, Fisher CR, Conte FA, Grumbach MM, Simpson ER. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci USA 1993;90:11673-7.
25. Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metab 1994;78:1287-92.
26. Harada N, Ogawa H, Shozu M, et al. Biochemical and molecular genetic analyses on placental aromatase (P-450AROM) deficiency. J Biol Chem 1992;267:4781-5.
27. Harada N, Ogawa H, Shozu M, Yamada K. Genetic studies to characterize the origin of the mutation in placental aromatase deficiency. Am J Hum Genet 1992;51:666-72.
28. AROM) deficiency associated with a novel mutation (R457X) in the CYP19 gene. Horm Res 1996;46:Suppl 2:4. abstract.
29. Vanderschueren D, van Herck E, Nijs J, Ederveen AGH, De Coster R, Bouillon R. Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Endocrinology 1997;138:2301-7
30. Vanderschueren D, Bouillon R. Androgens and bone. Calcif Tissue Int 1995;56:341-6.
31. Davis SR, Burger HG. Androgens and the postmenopausal woman. J Clin Endocrinol Metab 1996;81:2759-63.
32. Lindsay R, Cosman F. The pharmacology of estrogens in osteoporosis. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. San Diego, Calif: Academic Press, 1996:1063-6.
33. Heaney RP. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 1994; 9:1515-23.
34. Finkelstein JS, O'Dea LS, Whitcomb RW, Crowley WJ Jr. Sex steroid control of gonadotropin secretion in the human male. II. Effects of estradiol administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 1991;73:621-8.
35. Bagatell CJ, Dahl KD, Bremner WJ. The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol. J Androl 1994;15:15-21.
36. Kletter GB, Padmanabhan V, Beitins IZ, Marshall JC, Kelch RP, Foster CM. Acute effects of estradiol infusion and naloxone on luteinizing hormone secretion in pubertal boys. J Clin Endocrinol Metab 1997;82:4010-4.
37. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC. Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997;100:1755-9.
38. Greendale GA, Edelstein ES, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997;12:1833-43.
39. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-74.
40. Bernecker PM, Willvonsder R, Resch H. Decreased estrogen levels in male patients with primary osteoporosis. J Bone Miner Res 1995;10:Suppl: S445. abstract.
41. Center JR, Nguyen TV, White CP, Eisman JA. Male osteoporosis predictors: sex hormones and calcitropic hormones. J Bone Miner Res 1997; 12:Suppl 1:S368. abstract.
42. Anderson FH, Francis RM, Peaston RT, Wastell HJ Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res 1997;12:472-8.